Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results

ard-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contact

David A. Ramsay Karen Sparks / Joleen Schultz

Chief Financial Officer Mentus

(858) 704-8260 (858) 455-5500, x275/x215




Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006


Product sales $98,170 $115,206 $639,590 $670,625

Revenue under


agreements 1,239,739 311,121 3,159,931 311,121

Total Revenues 1,337,909 426,327 3,799,521 981,746


Cost of sales 29,229 41,399 240,429

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
(Date:10/8/2015)... 8, 2015  Today the Wyss Institute for Biologically ... its start-up company Opsonix Inc. The announcement ... Office of Technology Development (OTD) and Opsonix Inc. ... for clinical use. --> ... million people every year in the U.S. — more ...
(Date:10/7/2015)... 8, 2015 ... accounts for largest bioinformatics market share due ... discovery and development process says this research ... . --> ... of applications, the bioinformatics market is segmented ...
(Date:10/7/2015)... Oct. 7, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of targeted antiviral ... offering of 5,000,000 shares of its common stock and ... Company,s common stock at a fixed combined price to ... and warrants will be issued separately.  The warrants will ...
Breaking Biology Technology:
... ... Finance Organizations , ... Redwood Shores, California (PRWEB) February 24, 2010 -- Model N , Inc., the ... Contract Authoring solution, which extends the Model N Revenue Management Suite by allowing business ...
... ... ... ... ...
... have discovered that, under the right conditions, newly ... tiny spaces between the geometric clusters of atoms ... This finding, detailed recently in the journal ... becoming more ubiquitous in the fabrication of microdevices ...
Cached Biology Technology:
(Date:9/9/2015)... 2015  NuData Security announced today that it ... the company,s commitment to protecting organizations and individuals ... NuData Security,s online fraud detection solution, NuDetect, has ... The product combines continual analysis and behavioral biometrics ... from fraudulent behavior, allowing the company to detect ...
(Date:9/2/2015)... , Sept. 2, 2015 About hand geometry ... enterprises, banks, government organizations, telecommunication and hospitals as well ... identity badges, and numeric keypads are used to prevent ... of palm and fingers of an individual, width of ... scanners with infrared light and reflectors can be used ...
(Date:9/1/2015)... , Sept. 1, 2015  Automation and pre-processing ... airport passenger screening. This is the first step ... process will become unintrusive. An assortment of portal ... voluntary background investigations will transform the passenger screening ... Sullivan, Global Airport Passenger Screening Market ...
Breaking Biology News(10 mins):
... certain fish are capable of glowing red. Research published ... of fish fluorescing vivid red light. Due to ... which look red under normal conditions appear grey or ... the belief among marine biologists that red colours are ...
... , Researchers at the U.S. National Institutes of Health ... simple antiviral drug developed decades ago suppresses HIV in patients ... in the Sept. 11 issue of the journal Cell ... led by Dr. Leonid Margolis made the initial discovery, while ...
... press release is available in German . ... UFZ German scientist found that the worldwide economic ... bees mainly, was 153 billion in 2005 for the ... to 9.5% of the total value of the world ...
Cached Biology News:
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... Performance, 5 ml. The same high ... Streptavidin columns for fast, reliable purification ... Tricorn 5/50 GL, XK 16/20, or ... are required.Extremely useful for exploiting either ...
Biology Products: